Analysts Are Bullish on Top Healthcare Stocks: AC Immune SA (ACIU), Roche Holding AG (RHHVF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AC Immune SA (ACIUResearch Report) and Roche Holding AG (RHHVFResearch Report) with bullish sentiments.

AC Immune SA (ACIU)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA today and set a price target of $16.00. The company’s shares closed last Tuesday at $4.49, close to its 52-week low of $3.45.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 39.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $15.00 average price target, implying a 258.9% upside from current levels. In a report issued on March 22, Leerink Partners also maintained a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Roche Holding AG (RHHVF)

In a report released today, Keyur Parekh from Goldman Sachs maintained a Buy rating on Roche Holding AG, with a price target of CHF465.00. The company’s shares closed last Tuesday at $388.70.

Parekh has an average return of 12.6% when recommending Roche Holding AG.

According to TipRanks.com, Parekh is ranked #2162 out of 7928 analysts.

Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $432.42, implying a 10.1% upside from current levels. In a report issued on March 17, Deutsche Bank also maintained a Buy rating on the stock with a CHF425.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACIU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More